Depending on how the trial is set up they may have access to some parts of blinded data. In this indication and situation even blinded data may reveal quite much about how trial is going.
My opinion is that protocol has been designed so that the company doesn't have access to even to blinded data while trial is ongoing exactly because of this. But I think FDA rules allow it so there's some gray area here and no-one knows how it is unless they have access to protocol.
Other thing to consider is that after all data is collected blinded data may become available before the actual results are ready. So company and especially Dr Alkon will know fairly much already before we get actual results.
News 
Market Data 
Discover 
